Gyre Therapeutics' stock is volatile - I'm upholding my "Hold" rating due to uncertain long-term prospects and potential dilution from future funding needs. The company's products include Etuary ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gyre Therapeutics Inc. SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis ...

For their study, the researchers made projections using global climate models that accurately represent the Beaufort Gyre. The Beaufort Gyre is a massive wind-driven circular ocean current in the ...

SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), reported the sale of 4,000 shares of common stock over two consecutive days, according to a recent SEC ...

When the Kīlauea Volcano erupted in May 2018, an enormous amount of ash was released into the atmosphere in a plume nearly ...

The stock price didn't jump after Gyre Therapeutics, Inc. (NASDAQ:GYRE) posted decent earnings last week. We did some digging and believe investors may be worried about some underlying factors in ...

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company with clinical development programs focusing on ...

Gyre plans to submit an IND application in 2026. For the full year 2025, the Company expects to generate revenues of $118 to $128 million, representing growth of 11.3% to 20.8% over 2024 revenue ...

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated ...